<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01099748</url>
  </required_header>
  <id_info>
    <org_study_id>A5271031</org_study_id>
    <nct_id>NCT01099748</nct_id>
  </id_info>
  <brief_title>Estimate The Effect Of Lersivirine On The Pharmacokinetics Of S- And R-Methadone</brief_title>
  <official_title>Open Label, Single-Sequence Study To Estimate The Effect Of Lersivirine (UK-453,061) On S- And R-Methadone In Subjects Receiving Chronic Methadone Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to estimate the effect of lersivirine on the pharmacokinetics
      of R-methadone and S-methadone and to investigate the safety and tolerability of lersivirine
      when co-administered with methadone. Symptoms of methadone withdrawal will also be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R-methadone and S-methadone plasma pharmacokinetic parameters: AUC24, Cmax, Tmax, and C24h on Days 1 and 11</measure>
    <time_frame>Day 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and toleration assessed by spontaneous reporting of adverse events, vital signs, 12-lead ECG and laboratory safety assessments</measure>
    <time_frame>Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of methadone withdrawal as assessed by the Short Opiate Withdrawal Scale (SOWS), Desires for Drug Questionnaire (DDQ) and Pupillary Diameter measurement performed on Days 0 -12.</measure>
    <time_frame>Day 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Methadone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose of methadone must not change from 1 week prior to study start and through the duration of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lersivirine + Methadone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone</intervention_name>
    <description>Methadone 50 - 150 mg QD (Day 1)</description>
    <arm_group_label>Methadone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lersivirine + Methadone</intervention_name>
    <description>Lersivirine 1000 mg QD + Methadone 50 - 150 mg QD (Days 2-11)</description>
    <arm_group_label>Lersivirine + Methadone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects (Healthy is defined as no clinically relevant
             abnormalities identified by a detailed medical history except drug abuse), full
             physical examination, including blood pressure and pulse rate measurement, 12-lead ECG
             and clinical laboratory tests).

          -  Body Mass Index (BMI) of 17.5 to 35.5 kg/m2; and a total body weight &gt;50 kg (110 lbs).

          -  Receiving stable methadone maintenance treatment for at least 3 months (dose range
             50-150 mg QD).

        Exclusion Criteria:

          -  Subjects on therapy for Hepatitis B and/or Hepatitis C; Evidence of impaired liver
             function (ie, AST and/or ALT greater than 3 times the upper limit of normal, total
             bilirubin &gt;1.5 times the upper limit of normal, albumin &lt;3.5 g/dL).

          -  12-lead ECG demonstrating QTc &gt;450 msec for males and QTc &gt;470 msec for females or any
             other clinically significant abnormalities at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5271031&amp;StudyName=Estimate%20The%20Effect%20Of%20Lersivirine%20On%20The%20Pharmacokinetics%20Of%20S-%20And%20R-Methadone</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2010</study_first_submitted>
  <study_first_submitted_qc>April 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2010</study_first_posted>
  <last_update_submitted>August 26, 2010</last_update_submitted>
  <last_update_submitted_qc>August 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Drug interaction</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>lersivirine</keyword>
  <keyword>methadone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

